Gilead Sciences, Inc.'s strong sales growth in Veklury, Livdelzi, and Trodelvy shows promise for long-term financial success.

Gilead Sciences (GILD) is expected to deliver a year-over-year decline in earnings on lower revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook ...

With a market cap of $121,1 billion, Gilead Sciences, Inc. (GILD) is a leading biopharmaceutical company specializing in the ...

Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

Bullish option flow detected in Gilead (GILD) with 14,401 calls trading, 4x expected, and implied vol increasing over 4 points to 27.50%.

Gilead Sciences Inc (GILD) stock saw a modest uptick, ending the day at $97.2 which represents a slight increase of $0.25 or 0.26% from the prior close of $96.95. The stock opened at $96.73 and ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 ...

In a report released today, Brian Abrahams from RBC Capital maintained a Hold rating on Gilead Sciences (GILD – Research Report), with a price ...

Gilead is expected to enhance its efficiency through leveraging Cognizant’s expertise in AI and advanced technology ...